Serological Test for SARS-CoV-2

­

Application

Clinical assay for detecting SARS-CoV-2 neutralizing antibodies.

Key Benefits

  • Highly specific and sensitive.
  • Fewer false positives than commercially available tests.

Market Summary

SARS-CoV-2 is currently causing a devastating pandemic and there is a pressing need to understand the dynamics, specificity, and neutralizing potency of the immune response during acute infection. COVID-19 serological tests are used to assess immunity and predict patient outcomes; however, many of the existing tests suffer from high error.

Technical Summary

The SARS-CoV-2 receptor binding domain (RBD) interacts with the ACE2 receptor to infect cells. RBD-specific IgG antibody responses are rapidly induced during severe and moderate acute COVID-19 infection, with most patients showing RBD-specific antibody responses by 6 days post-PCR confirmation. Researchers have developed and validated a sensitive and selective RBD-based clinical assay that correlates with viral neutralization.

Developmental Stage

Validated with retrospective clinical samples.

Publication: https://www.medrxiv.org/content/10.1101/2020.05.03.20084442v1.full-text

Patent Information

App Type Country Serial No. Patent No. File Date Issued Date Patent Status
Nationalized PCT - United States United States 17/922,670   11/1/2022   Pending
Tech ID: 20171
Published: 1/24/2022